CatalystMarker
← board

ELAN

distress 2/10 · well-funded / low risk
$25.16-1%today-6% from 52w high
elanco.com9,400 employeesFounded 1954Indianapolis, INDrug Manufacturers - Specialty & Generic
Lead: canine dermatitis
Revenue
$1371M
Liquidity
$428M
Runway
Shares 1y
+1%

Price & events

+1.0% over 6M
$19.80$23.32$26.84Jan 26Apr 26Jul 2615.0Mrating: TD Cowen: Buy (2026-06-18)rating: Citigroup: Buy (2026-05-07)rating: JP Morgan: Overweight (2026-05-07)rating: Citigroup: Buy (2026-04-15)rating: Keybanc: Overweight (2026-02-25)rating: Morgan Stanley: Equal-Weight (2026-02-25)rating: Leerink Partners: Outperform (2026-02-24)rating: JP Morgan: Overweight (2026-02-19)
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-3.0%
1W
+8.5%
1M
+12.4%
3M
+3.1%
6M
+67.5%
1Y
+89.7%
2Y
-31.1%
5Y
-17.5%
All

Overview

Market Cap
$12.57B
Enterprise Value
$15.87B
Volume
302.32K
52 Week Range
$13.68 – $26.84
Total Shares
499.45M
Float Shares
494.82M
Short %
11.21%
% Held by Insiders
1.22%
% Held by Institutions
111.51%
RVOL
0.07x
Beta
1.69

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 4

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 499,449,583 · 0 offerings/1y · 0 PIPEs
  • 2025-11-038-Kmaterial_agreement
  • 2025-06-268-Kmaterial_agreement
  • 2024-08-138-Kmaterial_agreement
  • 2024-07-08SC 13G/Astrategic_stake
  • 2024-07-038-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $30 (+19% upside) · 14 analysts
  • 2026-06-18TD CowenBuy
  • 2026-05-07CitigroupBuy
  • 2026-05-07JP MorganOverweight
  • 2026-04-15CitigroupBuy
  • 2026-02-25KeybancOverweight
  • 2026-02-25Morgan StanleyEqual-Weight

Competitors — canine dermatitis

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.